VanEck Biotech ETF
BBH
79 hedge funds and large institutions have $211M invested in VanEck Biotech ETF in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 14 closing their positions.
255% more call options, than puts
Call options by funds: $3.8M | Put options by funds: $1.07M
24% more capital invested
Capital invested by funds: $170M → $211M (+$41.1M)
3.62% more ownership
Funds ownership: 29.58% → 33.2% (+3.6%)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
8% less funds holding
Funds holding: 86 → 79 (-7)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$28.2M |
| 2 |
VF
Virtu Financial
New York
|
+$5.95M |
| 3 |
MLL
Moody Lynn & Lieberson
Boston,
Massachusetts
|
+$4.57M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.03M |
| 5 |
ACM
Aviance Capital Management
Sarasota,
Florida
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Colony Group
Boston,
Massachusetts
|
-$4.79M |
| 2 |
SG Americas Securities
New York
|
-$2.58M |
| 3 |
AL
Aspiriant LLC
Los Angeles,
California
|
-$2.5M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.71M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.69M |
BBH Hedge Fund Activity: Q1 2017 in Review
79 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q1 2017, worth a combined $211M — up 24% from $170M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of BBH and 8 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 23 added.
The largest buyer was AllianceBernstein, adding an estimated $28.2M. The largest seller was Colony Group, exiting entirely with an estimated $4.79M sold.
- 79 institutional investors held VanEck Biotech ETF (BBH) as of Q1 2017, down from 86 in Q4 2016.
- Funds reported $211M of VanEck Biotech ETF stock for Q1 2017, up 24% quarter-over-quarter.
- 8 funds opened new VanEck Biotech ETF positions in Q1 2017 and 14 closed out, a net change of -6 holders.
- The largest VanEck Biotech ETF buyer in Q1 2017 was AllianceBernstein, an estimated $28.2M added.
- The largest VanEck Biotech ETF seller in Q1 2017 was Colony Group, an estimated $4.79M sold.
Based on aggregated 13F filings for Q1 2017.